Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease.
about
CNS active O-linked glycopeptidesOpioid glycopeptide analgesics derived from endogenous enkephalins and endorphinsLong-term effect of sub-anesthetic ketamine in reducing L-DOPA-induced dyskinesias in a preclinical model.CNS penetration of the opioid glycopeptide MMP-2200: a microdialysis study.Delta Opioid Pharmacology in Parkinson's Disease.
P2860
Effects of the novel glycopeptide opioid agonist MMP-2200 in preclinical models of Parkinson's disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Effects of the novel glycopept ...... models of Parkinson's disease.
@ast
Effects of the novel glycopept ...... models of Parkinson's disease.
@en
type
label
Effects of the novel glycopept ...... models of Parkinson's disease.
@ast
Effects of the novel glycopept ...... models of Parkinson's disease.
@en
prefLabel
Effects of the novel glycopept ...... models of Parkinson's disease.
@ast
Effects of the novel glycopept ...... models of Parkinson's disease.
@en
P2093
P2860
P1433
P1476
Effects of the novel glycopept ...... models of Parkinson's disease.
@en
P2093
Frank Porreca
Lajos Szabò
Leslie A Zuniga
Robin Polt
Scott J Sherman
Torsten Falk
P2860
P356
10.1016/J.BRAINRES.2011.07.038
P407
P577
2011-07-23T00:00:00Z